18 results on '"Laborada J"'
Search Results
2. Lentiviral Gene Therapy in HSCs Restores Lineage-Specific Foxp3 Expression and Suppresses Autoimmunity in a Mouse Model of IPEX Syndrome
- Author
-
Jennifer Laborada, Roger P. Hollis, Katelyn E. Masiuk, Maria Grazia Roncarolo, Donald B. Kohn, Masiuk, K. E., Laborada, J., Roncarolo, M. G., Hollis, R. P., and Kohn, D. B.
- Subjects
Diarrhea ,Genetic enhancement ,Autoimmunity ,chemical and pharmacologic phenomena ,Tregs ,Biology ,medicine.disease_cause ,T-Lymphocytes, Regulatory ,Viral vector ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Genes, Reporter ,FoxP3 ,Genetics ,medicine ,IPEX ,Animals ,Humans ,Cell Lineage ,IL-2 receptor ,030304 developmental biology ,Autoimmune disease ,0303 health sciences ,autoimmunity ,Lentivirus ,FOXP3 ,hemic and immune systems ,Forkhead Transcription Factors ,Genetic Diseases, X-Linked ,Cell Biology ,Genetic Therapy ,IPEX syndrome ,Immune dysregulation ,medicine.disease ,Hematopoietic Stem Cells ,gene therapy ,Disease Models, Animal ,Diabetes Mellitus, Type 1 ,Immune System Diseases ,Cancer research ,Molecular Medicine ,030217 neurology & neurosurgery - Abstract
Summary Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a devastating autoimmune disease caused by mutations in FoxP3, a transcription factor required for the development and function of regulatory T cells (Treg cells). Allogeneic hematopoietic stem cell transplant (HSCT) can be curative, but suitable donors are often unavailable. Here, we demonstrate a strategy for autologous HSCT and gene therapy utilizing a lentiviral vector (LV) to restore FoxP3 expression under the control of endogenous human FOXP3 regulatory elements. Both murine transplant models and humanized mice engrafted with LV-modified HSCs show high levels of LV expression selective for CD4+CD25+FoxP3+ Treg cells. LV transduction of scurfy (FoxP3mut) HSCs restores development of functional FoxP3+ Treg cells that suppress T cell proliferation in vitro and rescue the scurfy autoimmune phenotype in vivo. These findings demonstrate preclinical efficacy for the treatment of IPEX patients by autologous HSC transplant and may provide valuable insights into new cell therapies for autoimmunity.
- Published
- 2019
3. Growth in the Cost of Biologics in Medicare Beneficiaries, 2017 to 2019.
- Author
-
Laborada J, Shin L, Lee C, Shahsavari S, Egeberg A, and Wu JJ
- Abstract
Competing Interests: DISCLOSURES.: Dr. Laborada, Dr. Shin, Dr. Lee, Mr. Shahsavari, and Dr. Egeberg report no conflicts of interest. Dr. Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Aristea Therapeutics, Bausch Health (Ortho Dermatologics), Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Dr. Reddy's Laboratories, Eli Lilly, Galderma, Janssen, LEO Pharma, Mindera, Novartis, Regeneron, Sanofi Genzyme, Solius, Sun Pharmaceutical, UCB, and Zerigo Health.
- Published
- 2024
4. Artificial intelligence tools may be superior to traditional approaches for translating patient handouts: A pilot study.
- Author
-
Dong S, Zhang S, Park H, De La Rosa J, Al-Nabti A, Pham VX, Cedeno A, Toledo I, Jallorina A, Laborada J, Sun B, Wang R, and Hightower G
- Abstract
Competing Interests: None disclosed.
- Published
- 2024
- Full Text
- View/download PDF
5. Post-Hyaluronic Acid Filler Reaction Treated With Abrocitinib: A Case Report.
- Author
-
Lopez MHP, Guenin SH, Laborada J, and Lebwohl MG
- Subjects
- Humans, Female, Hyaluronoglucosaminidase, Sulfonamides, Hyaluronic Acid adverse effects, Excipients, Pyrimidines
- Abstract
Post-hyaluronic acid filler nodules are uncommon, unpredictable complications that present a challenge to clinical therapy. We report a case of a female in her fifties who developed edema and nodules 6 weeks after hyaluronic acid (HA) filler injection. After minimal improvement with oral steroids and intralesional hyaluronidase, a trial of oral abrocitinib was initiated, which yielded significant clinical improvement. Thus, abrocitinib may be a novel therapeutic option for delayed-onset nodules following injection of hyaluronic acid. J Drugs Dermatol. 2024;23(1):1355-1356. doi:10.36849/JDD.7271.
- Published
- 2024
- Full Text
- View/download PDF
6. Psoriasis and healthcare utilization: a cross-sectional study.
- Author
-
Shin L, Lee C, Laborada J, Egeberg A, and Wu JJ
- Subjects
- Humans, Cross-Sectional Studies, Delivery of Health Care, Patient Acceptance of Health Care, Psoriasis
- Published
- 2023
- Full Text
- View/download PDF
7. COVID-19 vaccine side effects in patients with and without atopic dermatitis.
- Author
-
Shin L, Shahsavari S, Laborada J, Lee C, Thyssen JP, and Wu JJ
- Subjects
- Humans, Iatrogenic Disease, COVID-19 prevention & control, COVID-19 Vaccines adverse effects, Dermatitis, Atopic drug therapy, Drug-Related Side Effects and Adverse Reactions
- Published
- 2023
- Full Text
- View/download PDF
8. Adverse Effects of the COVID-19 Vaccine in Patients With Psoriasis.
- Author
-
Shin L, Shahsavari S, Lee C, Laborada J, Egeberg A, and Wu JJ
- Subjects
- Humans, COVID-19 Vaccines adverse effects, COVID-19 prevention & control, Drug-Related Side Effects and Adverse Reactions, Psoriasis
- Published
- 2023
- Full Text
- View/download PDF
9. Association Between Psoriasis and Food Insecurity Among United States Adults.
- Author
-
Shin L, Laborada J, Lee C, Egeberg A, and Wu JJ
- Abstract
Competing Interests: DISCLOSURES: Ms. Shin, Ms. Laborada, and Ms. Lee report no conflicts of interest. Dr. Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Aristea Therapeutics, Bausch Health (Ortho Dermatologics), Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Dr. Reddy's Laboratories, Eli Lilly, Galderma, Janssen, LEO Pharma, Mindera, Novartis, Regeneron, Sanofi Genzyme, Solius, Sun Pharmaceutical, UCB, and Zerigo Health. Dr. Egeberg has received research funding from Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd., Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and Janssen Pharmaceuticals.
- Published
- 2022
10. Multiple skin neoplasms at one site (MUSK IN A NEST): collision tumor consisting of epidermal (macular seborrheic keratosis) and dermal (lichen amyloidosis) components.
- Author
-
Laborada J, Erickson CP, Calame A, and Cohen PR
- Subjects
- Humans, Female, Adult, Retrospective Studies, Receptors, Cholinergic, Receptor Protein-Tyrosine Kinases, Keratosis, Seborrheic pathology, Skin Neoplasms pathology, Skin Diseases, Genetic, Amyloidosis pathology
- Abstract
A collision tumor is a neoplastic lesion comprised of two or more tumors consisting of distinct cell populations in the concurrent location. Multiple skin neoplasms at one site (MUSK IN A NEST) is a term recently coined to describe two or more cutaneous benign or malignant tumors occurring at the same anatomic site. In retrospective studies, seborrheic keratosis and cutaneous amyloidosis have both individually been documented as a component of a MUSK IN A NEST. This report describes a 42-year-old woman who presented with a pruritic skin condition on her arms and legs of 13 years' duration. Skin biopsy results showed epidermal hyperplasia with hyperkeratosis, hyperpigmentation of the basal layer with mild acanthosis, and evidence of amyloid deposition in the papillary dermis. Based on the clinical presentation and pathology findings, a concurrent diagnosis of macular seborrheic keratosis and lichen amyloidosis was established. A MUSK IN A NEST consisting of a macular seborrheic keratosis and lichen amyloidosis is likely a more common occurrence than implied by the paucity of published cases of this phenomenon.
- Published
- 2022
- Full Text
- View/download PDF
11. What's New in Topicals for Atopic Dermatitis?
- Author
-
Kleinman E, Laborada J, Metterle L, and Eichenfield LF
- Subjects
- Administration, Topical, Adult, Calcineurin Inhibitors adverse effects, Child, Humans, Quality of Life, Dermatitis, Atopic drug therapy, Dermatitis, Atopic pathology
- Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin condition that can have tremendous impact on quality of life for affected children and adults. First-line therapy for acute management of AD includes topical therapies such as corticosteroids, calcineurin inhibitors, and, more recently, the phosphodiesterase inhibitor crisaborole. Topical agents have remained the mainstay therapy for decades; however, there has been a longstanding need for topical therapies with high efficacy and low risk of adverse effects with long-term use. Given the ongoing advances in understanding the pathogenesis of AD, there are novel targets for pharmacological intervention. We are now in an unprecedented time with more than 40 topical treatments in the pipeline for AD in addition to many developments and treatments on the horizon. This review summarizes selected therapeutic topical agents in later phases of development that target various aspects in the pathogenesis of AD such as Janus kinase inhibition (ruxolitinib and delgocitinib), phosphodiesterase-4 inhibition (roflumilast and difamilast), aryl hydrocarbon modulation (tapinarof), and modulation of the microbiome. We also review novel targeted therapies that are in early phase clinical trials, including AMTX-100, BEN-2293, and PRN473. Preliminary findings on efficacy and tolerability of most of these agents are promising, but further studies are warranted to evaluate the long-term safety and efficacy of these novel agents against the current standard of care., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
12. Atopic dermatitisReview of comorbidities and therapeutics.
- Author
-
Appiah MM, Haft MA, Kleinman E, Laborada J, Lee S, Loop L, Geng B, and Eichenfield LF
- Subjects
- Comorbidity, Humans, Dermatitis, Atopic drug therapy, Dermatitis, Atopic epidemiology, Quality of Life
- Abstract
Atopic dermatitis (AD) is a very common skin disease associated with substantial burdens on patient health and quality of life. Knowledge regarding the pathogenesis of AD has expanded within recent years, leading to novel and efficacious therapeutic agents. Similarly, our knowledge of the impact of AD on patient's mental and physical health has also expanded. This review summarizes updates on the evolution, comorbidities, and therapeutic options of AD. AD is associated with increased cardiovascular risk, allergic diseases, and adverse mental health outcomes. Topical and systemic therapeutics have drastically altered the landscape of AD therapy in recent years., (Copyright © 2022. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
13. Cutaneous Squamous Cell Carcinoma and Lichen Simplex Chronicus Successfully Treated with Topical Cannabinoid Oil: A Case Report and Summary of Cannabinoids in Dermatology.
- Author
-
Laborada J and Cohen PR
- Abstract
Cannabidiol is a member of the cannabinoids, consisting of a diverse class of compounds derived from Cannabis sativa . There are three types of cannabinoids based on origin: endocannabinoids (endogenous), phytocannabinoids (plant-derived), and synthetic cannabinoids (synthesized). The endocannabinoid system plays a key role in skin homeostasis, such as proliferation, differentiation, and inflammatory signaling. A 64-year-old woman with a history of multiple squamous cell carcinomas who presented with skin lesions on her bilateral dorsal hands is reported. Her skin biopsies showed lichen simplex chronicus on her left hand and squamous cell carcinoma on her right hand; both lesions resolved with topical application of 20% cannabidiol. Cutaneous adverse events associated with cannabinoid use and potential therapeutic uses of cannabinoids in inflammatory skin diseases and skin cancer are also summarized., Competing Interests: The authors have declared financial relationships, which are detailed in the next section., (Copyright © 2022, Laborada et al.)
- Published
- 2022
- Full Text
- View/download PDF
14. Tuberculosis-Associated Erythema Nodosum.
- Author
-
Laborada J and Cohen PR
- Abstract
Erythema nodosum is panniculitis that is frequently observed in women aged 18 to 34 years. It usually occurs as an idiopathic condition; however, it may be associated with drugs, infections, malignancy, pregnancy, and systemic illnesses. Erythema nodosum presents with the sudden onset of tender, warm, erythematous nodules typically on the ankles, knees, and shins. Although the pathogenesis has not been fully elucidated, evidence supports a delayed type IV hypersensitivity reaction. It is often a clinical diagnosis that does not require a biopsy; appropriate work-up and careful medication history are crucial to identifying an underlying etiology if present. This report describes a woman from Vietnam, a tuberculosis endemic country, who presented with erythema nodosum that was determined to be a sequela of latent tuberculosis. Several studies have demonstrated an association between erythema nodosum and tuberculosis, especially in endemic regions. Summarized data reveals the incidence of tuberculosis-associated erythema nodosum to be six percent; however, when individuals with either secondary erythema nodosum or infection-associated erythema nodosum are evaluated, the incidence of tuberculosis-associated erythema nodosum is 11% or 21%, respectively. Evaluation of erythema nodosum should include a tuberculin or QuantiFERON test, chest roentgenogram, and/or an acid-fast bacilli sputum culture if the diagnosis of tuberculosis is being considered., Competing Interests: The authors have declared financial relationships, which are detailed in the next section., (Copyright © 2021, Laborada et al.)
- Published
- 2021
- Full Text
- View/download PDF
15. Smoker's Mustache Revisited: Upper Lip Hair Yellow Discoloration Associated With Tobacco.
- Author
-
Laborada J and Cohen PR
- Abstract
Yellow hair discoloration (xanthotrichia) has been observed in several settings. Indeed, acquired xanthotrichia, in addition to environmental and occupational causes, can be observed secondary to either iatrogenic, topical, or systemic exposure to systemic drugs and certain systemic conditions: most commonly essential fatty acid deficiencies, protein deficiency, or vitamin B12 deficiency. Smoker's mustache refers to the acquired yellow discoloration of previously white hair on the cutaneous upper lip of men. These individuals are typically elderly and have a history of smoking either cigarettes, cigars, or pipes of several years' duration. The asymptomatic dyschromia often originates centrally, affecting the hair overlying the philtrum and expanding laterally. The condition is asymptomatic, and affected individuals are either unaware of the color change or not concerned with their altered appearance. Yellow to brown discoloration of the thumbnails, fingernails, or both (such as nicotine sign and/or harlequin nails) may be an accompanying clinical stigma to the smoker's mustache and a clue to the diagnosis. Management options include smoking cessation or hair removal of the discolored hair, or both; however, patients usually elect to continue smoking, maintain their facial hair, and continue to display their distinctive yellow smoker's mustache., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2021, Laborada et al.)
- Published
- 2021
- Full Text
- View/download PDF
16. Sun protection behaviors among people living with HIV.
- Author
-
Kellogg C, Mittal N, Hakimi K, Laborada J, Young Karris M, Bamford L, and Marsch AF
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Self Report, Skin Neoplasms etiology, Sunburn complications, Sunscreening Agents, Young Adult, HIV Infections psychology, Health Behavior, Skin Neoplasms prevention & control, Sunburn prevention & control
- Abstract
People living with HIV (PLWH) are at increased risk for both melanoma and nonmelanoma skin cancers, but there is currently no data on sun protection behaviors among PLWH. We created a 28-question paper survey to collect information on patient demographics and sun protection behaviors among PLWH. We found that although 71.6% of respondents reported spending at least 30 minutes to two hours in the sun daily, only 29.7% reported consistent use of sunscreen. In addition, 41.9% rarely or never received sunscreen counseling by their healthcare providers. There is therefore a need for increased training for healthcare providers in sun protection behavior counseling for PLWH.
- Published
- 2021
- Full Text
- View/download PDF
17. Lentiviral Gene Therapy in HSCs Restores Lineage-Specific Foxp3 Expression and Suppresses Autoimmunity in a Mouse Model of IPEX Syndrome.
- Author
-
Masiuk KE, Laborada J, Roncarolo MG, Hollis RP, and Kohn DB
- Subjects
- Animals, Diabetes Mellitus, Type 1 genetics, Diabetes Mellitus, Type 1 immunology, Diabetes Mellitus, Type 1 therapy, Diarrhea genetics, Disease Models, Animal, Forkhead Transcription Factors genetics, Genes, Reporter, Genetic Diseases, X-Linked genetics, Humans, Immune System Diseases genetics, Immune System Diseases immunology, Immune System Diseases therapy, Mice, T-Lymphocytes, Regulatory immunology, Autoimmunity, Cell Lineage, Diabetes Mellitus, Type 1 congenital, Diarrhea immunology, Diarrhea therapy, Forkhead Transcription Factors therapeutic use, Genetic Diseases, X-Linked immunology, Genetic Diseases, X-Linked therapy, Genetic Therapy, Hematopoietic Stem Cells metabolism, Immune System Diseases congenital, Lentivirus genetics
- Abstract
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a devastating autoimmune disease caused by mutations in FoxP3, a transcription factor required for the development and function of regulatory T cells (Treg cells). Allogeneic hematopoietic stem cell transplant (HSCT) can be curative, but suitable donors are often unavailable. Here, we demonstrate a strategy for autologous HSCT and gene therapy utilizing a lentiviral vector (LV) to restore FoxP3 expression under the control of endogenous human FOXP3 regulatory elements. Both murine transplant models and humanized mice engrafted with LV-modified HSCs show high levels of LV expression selective for CD4+CD25+FoxP3+ Treg cells. LV transduction of scurfy (FoxP3
mut ) HSCs restores development of functional FoxP3+ Treg cells that suppress T cell proliferation in vitro and rescue the scurfy autoimmune phenotype in vivo. These findings demonstrate preclinical efficacy for the treatment of IPEX patients by autologous HSC transplant and may provide valuable insights into new cell therapies for autoimmunity., (Copyright © 2018 Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
18. Improving Gene Therapy Efficiency through the Enrichment of Human Hematopoietic Stem Cells.
- Author
-
Masiuk KE, Brown D, Laborada J, Hollis RP, Urbinati F, and Kohn DB
- Subjects
- ADP-ribosyl Cyclase 1 metabolism, Animals, Antigens, CD34 metabolism, Gene Expression, Gene Transfer Techniques, Genes, Reporter, Genetic Therapy, Genetic Vectors genetics, Graft Survival, Hematopoietic Stem Cell Transplantation, Hematopoietic Stem Cells cytology, Humans, Immunomagnetic Separation, Immunophenotyping, Lentivirus genetics, Mice, Transgenes, Hematopoietic Stem Cells metabolism, Transduction, Genetic
- Abstract
Lentiviral vector (LV)-based hematopoietic stem cell (HSC) gene therapy is becoming a promising clinical strategy for the treatment of genetic blood diseases. However, the current approach of modifying 1 × 10
8 to 1 × 109 CD34+ cells per patient requires large amounts of LV, which is expensive and technically challenging to produce at clinical scale. Modification of bulk CD34+ cells uses LV inefficiently, because the majority of CD34+ cells are short-term progenitors with a limited post-transplant lifespan. Here, we utilized a clinically relevant, immunomagnetic bead (IB)-based method to purify CD34+ CD38- cells from human bone marrow (BM) and mobilized peripheral blood (mPB). IB purification of CD34+ CD38- cells enriched severe combined immune deficiency (SCID) repopulating cell (SRC) frequency an additional 12-fold beyond standard CD34+ purification and did not affect gene marking of long-term HSCs. Transplant of purified CD34+ CD38- cells led to delayed myeloid reconstitution, which could be rescued by the addition of non-transduced CD38+ cells. Importantly, LV modification and transplantation of IB-purified CD34+ CD38- cells/non-modified CD38+ cells into immune-deficient mice achieved long-term gene-marked engraftment comparable with modification of bulk CD34+ cells, while utilizing ∼7-fold less LV. Thus, we demonstrate a translatable method to improve the clinical and commercial viability of gene therapy for genetic blood cell diseases., (Copyright © 2017 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.